Blog
Feedback
schliessen

Filtern

 

Bibliotheken

Logo der Bibliothek

Logo FID Pharmazie PubPharm Discovery System Universitätsbibliothek Braunschweig Institut für Informationssysteme

Registry for the Evaluation of Safety and Effectiveness of the Seraph 100 Microbind Affinity Blood Filter in the Therapy of COVID-19 Patients (COSA) : = Registry of COVID-19 Patients Treated With the Seraph 100 Microbind Affinity Blood Filter

During the ongoing COVID-19 pandemic, millions of people have been infected with SARS- Cov-2 worldwide. In the absence of an approved vaccine or medical treatment, there is an emerging need for treatment options, especially in critically ill patients. Multiple pharmacological and non-pharmacological therapies are being investigated. In 2019, the Seraph® 100 Microbind® Affinity Blood Filter (ExThera Medical Corporation, CA, USA) was approved for the removal of pathogens in Europe. On April 17th the FDA granted Authorization for Emergency Use in patients with COVID-19 admitted to the ICU with confirmed or imminent respiratory failure.

Year of Publication: 2020
Published: Bethesda (Maryland), ClinicalTrials.gov, April 24, 2020
Language: English
Full text access: Full text access (free access)
Links: Full Text (clinicaltrials.gov)
Keywords: COVID-19
Clinical Study Status: Recruiting
Clinical Study
Forschungsbericht
Klinische Studie
Notes: Source: ClinicalTrials.gov (no modifications made)
ClinicalTrials.gov processed this data on June 05, 2020
Last update posted on ClinicalTrials.gov: April 24, 2020
Last updated: 2020-06-08
NCT ID:
    NCT04361500

Associated Publications

  • Associated records are being queried...
more (+)
Internes Format
LEADER 02396nam a22004572 4500
001 CTG00337162X
003 DE-627
005 20200609024431.0
007 cr uuu---uuuuu
008 200609s2020 xx |||||ot 00| ||eng c
028 5 2 |a CTg_2020-06-08.pp 
035 |a (DE-627)CTG00337162X 
035 |a (DE-599)NCTNCT04361500 
035 |a (NCT)COSA-8998 
035 |a (NCT)NCT04361500 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
084 |a PHARMAZIE  |q DE-84  |2 fid 
084 |a pha  |2 ssgn 
245 1 0 |a Registry for the Evaluation of Safety and Effectiveness of the Seraph 100 Microbind Affinity Blood Filter in the Therapy of COVID-19 Patients (COSA)  |b  = Registry of COVID-19 Patients Treated With the Seraph 100 Microbind Affinity Blood Filter 
246 3 1 |a Registry of COVID-19 Patients Treated With the Seraph 100 Microbind Affinity Blood Filter 
264 1 |a Bethesda (Maryland)  |b ClinicalTrials.gov  |c April 24, 2020 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Source: ClinicalTrials.gov (no modifications made) 
500 |a ClinicalTrials.gov processed this data on June 05, 2020 
500 |a Last update posted on ClinicalTrials.gov: April 24, 2020 
500 |a Last updated: 2020-06-08 
520 |a During the ongoing COVID-19 pandemic, millions of people have been infected with SARS- Cov-2 worldwide. In the absence of an approved vaccine or medical treatment, there is an emerging need for treatment options, especially in critically ill patients. Multiple pharmacological and non-pharmacological therapies are being investigated. In 2019, the Seraph® 100 Microbind® Affinity Blood Filter (ExThera Medical Corporation, CA, USA) was approved for the removal of pathogens in Europe. On April 17th the FDA granted Authorization for Emergency Use in patients with COVID-19 admitted to the ICU with confirmed or imminent respiratory failure. 
650 4 |a Clinical Study Status: Recruiting 
650 4 |a COVID-19 
650 4 |a Clinical Study 
650 4 |a Klinische Studie 
655 7 |a Forschungsbericht  |2 gnd-content 
710 2 |a Hannover Medical School  |e Herausgebendes Organ  |4 isb 
856 4 0 |u https://clinicaltrials.gov/show/NCT04361500  |z Kostenfrei  |3 Volltext 
912 |a GBV_CTG 
936 u w |j 2020  |b 24  |c 04 
951 |a BO 
952 |j 2020  |b 24  |c 04